pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·54m ago·1 min read
save

Mass General Brigham drops Dana-Farber from its Medicare Advantage network starting Oct 1

Sep 4, 2026·read at STAT ↗RegulatoryNegative

Mass General Brigham announced that its Medicare Advantage plan will no longer include Dana-Farber Cancer Institute in its provider network beginning October 1, following a recent split between the two health systems.

The plan, which serves roughly 20,500 members, currently has only a small portion of enrollees receiving cancer treatment at Dana-Farber at any given time.

One affected patient, an 88‑year‑old retired accountant who has seen the same oncologist for decades, will need to either locate a new cancer specialist within the plan’s network or consider switching insurance to maintain his current care.

The change highlights ongoing tensions in Boston’s hospital landscape as integrated health systems renegotiate relationships and network affiliations.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Top Boston hospitals clash over Medicare Advantage network after split”

read at STAT ↗
365 words · retrieved 29m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Dana-Farber Cancer Institute Inc2Ultragenyx Pharmaceutical Inc.
topics
Oncology8Approval2NeurologyRare Disease

related stories

  • 2h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • 3h agoIonis’ rare neurology drug approved; Pfizer inks an ADC dealBioPharma Dive
  • 1d agoCapricor, Replimune illustrate why FDA must listen to rare disease specialistsBioSpace
  • 4d agoBMS’ neuro renaissance was built on back of Celgene mega-mergerBioSpace
  • Aug 20Chutes & Ladders—Neumora shuffles leadership ahead of INDFierce Biotech